Navigation Links
Cepheid Announces Board of Directors Changes

SUNNYVALE, Calif., Feb. 14, 2013 /PRNewswire/ -- Cepheid (Nasdaq: CPHD) today announced that its Board of Directors has elected John Bishop as Chairman of the Board of Directors and named Cristina Kepner as Lead Independent Director, effective February 12, 2013.

Mr. Bishop, currently Cepheid's Chief Executive Officer, succeeds Thomas Gutshall , who will continue to serve on Cepheid's board as a director.  Mr. Bishop has been Cepheid's Chief Executive Officer and a director since April 2002.

"It is an honor to succeed Tom Gutshall as Chairman of Cepheid," said John Bishop .  "Since 1996, Tom has contributed immeasurably to Cepheid's vision and direction, as co-founder and Chairman of the Board and as our original Chief Executive Officer.  In addition to his breadth of experience in life sciences, Tom brings his deep experience with our proprietary technologies, and I look forward to his continuing contributions as a director."

" Cris Kepner has been a significant contributor on the Cepheid Board for 15 years," added John Bishop .  "Given her background and tenure on the Board, Cris brings broad market knowledge as well as a deep understanding of Cepheid, which will be ever more valuable in her role as Lead Independent Director."

Newly appointed Lead Independent Director Cristina Kepner has been a Cepheid director since 1998.  Ms. Kepner was formerly Executive Vice President and Corporate Finance Director of Invemed Associates, an investment bank, where she worked for 22 years.  Additionally, Ms. Kepner served as a director of Monogram Biosciences Inc. from May 1996 until August 2009, and as a director and later Chairman of the board of directors of Quipp, Inc. from January 1995 until June 2008.

About CepheidBased in Sunnyvale, Calif., Cepheid (Nasdaq: CPHD) is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests.  By automating highly complex and time-consuming manual procedures, the company's solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases.  Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit Media Inquiries:For Investor Inquiries:Jared Tipton

Cepheid Corporate Communications

Tel: (408) 400 8377

Jacquie Ross

Cepheid Investor Relations

Tel: (408) 400 8329

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Welcomes Senior Vice President of Human Resources
2. Cepheid Reports Fourth Quarter and Full Year 2011 Results
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
5. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
6. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
7. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
8. Cepheid Reports 2012 Second Quarter Results
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... SAN DIEGO , Dec. 1, 2015 /PRNewswire/ ... that uses allogeneic stem cells for cardiovascular indications, ... clinical trial protocol based on recommendations from a ... leaders and its Scientific Advisory Board members ... boards analyzed preliminary Phase IIa safety and efficacy ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
(Date:11/30/2015)... ... 30, 2015 , ... Global Stem Cells Group ... from Central America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, ... 2016. Testart will present and discuss new trends in anti-aging stem cell treatments, ...
(Date:11/30/2015)... MONTREAL , Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... that it has joined the American Business Act on Climate ... economy that are standing with the Obama Administration to demonstrate ... for a strong outcome to the COP21 Paris ... . --> Sarnia, Canada . ...
Breaking Biology Technology:
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):